<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(1)</volume><submitter>Subbarayan K</submitter><funding>Wilhelm Sander-Stiftung</funding><funding>Deutsche Forschungsgemeinschaft</funding><funding>Deutsche Krebshilfe</funding><pubmed_abstract>The extracellular matrix component biglycan (BGN) plays an essential role in various physiological and pathophysiological processes. A deficient BGN expression associated with reduced immunogenicity was found in HER-2/neu-overexpressing cells. To determine whether BGN is suppressed by oncogene-driven regulatory networks, the expression and function of BGN was analyzed in murine and human BGN&lt;sup>low&lt;/sup>/BGN&lt;sup>high&lt;/sup> K-RAS&lt;sup>G12V&lt;/sup>-transformed model systems as well as in different patients' datasets of colorectal carcinoma (CRC) lesions. K-RAS-mutated CRC tissues expressed low BGN mRNA and protein levels when compared to normal colon epithelial cells, which was associated with a reduced patients' survival. Transfection of BGN in murine and human BGN&lt;sup>low&lt;/sup> K-RAS-express</pubmed_abstract><journal>Oncoimmunology</journal><pagination>2069214</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9067524</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.</pubmed_title><pmcid>PMC9067524</pmcid><pubmed_authors>Subbarayan K</pubmed_authors><pubmed_authors>Massa C</pubmed_authors><pubmed_authors>Steven A</pubmed_authors><pubmed_authors>Wickenhauser C</pubmed_authors><pubmed_authors>Bethmann D</pubmed_authors><pubmed_authors>Biehl K</pubmed_authors><pubmed_authors>Seliger B</pubmed_authors><pubmed_authors>Leisz S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.</name><description>The extracellular matrix component biglycan (BGN) plays an essential role in various physiological and pathophysiological processes. A deficient BGN expression associated with reduced immunogenicity was found in HER-2/neu-overexpressing cells. To determine whether BGN is suppressed by oncogene-driven regulatory networks, the expression and function of BGN was analyzed in murine and human BGN&lt;sup>low&lt;/sup>/BGN&lt;sup>high&lt;/sup> K-RAS&lt;sup>G12V&lt;/sup>-transformed model systems as well as in different patients' datasets of colorectal carcinoma (CRC) lesions. K-RAS-mutated CRC tissues expressed low BGN mRNA and protein levels when compared to normal colon epithelial cells, which was associated with a reduced patients' survival. Transfection of BGN in murine and human BGN&lt;sup>low&lt;/sup> K-RAS-express</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-26T04:38:02.876Z</modification><creation>2025-04-06T11:12:29.271Z</creation></dates><accession>S-EPMC9067524</accession><cross_references><pubmed>35529675</pubmed><doi>10.1080/2162402X.2022.2069214</doi></cross_references></HashMap>